Last update 04 Sep 2025

Adebrelimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
HTI-1088, HTI-1316, SHR 1316
+ [2]
Target
Action
inhibitors
Mechanism
PDL1 inhibitors(Programmed death-ligand 1 inhibitors)
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationBreakthrough Therapy (China), Special Review Project (China)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Extensive stage Small Cell Lung Cancer
China
28 Feb 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
PD-L1 positive Triple Negative Breast CancerPhase 3
China
01 Sep 2025
Metastatic Gastroesophageal Junction AdenocarcinomaPhase 3
China
18 Aug 2025
Muscle Invasive Bladder CarcinomaPhase 3
China
25 Apr 2025
Advanced Hepatocellular CarcinomaPhase 3
China
28 Oct 2024
Non-squamous non-small cell lung cancerPhase 3
China
29 Mar 2024
Non-squamous non-small cell lung cancerPhase 3
China
29 Mar 2024
Small cell lung cancer limited stagePhase 3
China
20 Jan 2021
Non-small cell lung cancer stage IIIBPhase 3
China
14 Jul 2020
Resectable Lung Non-Small Cell CarcinomaPhase 3
China
10 Jul 2020
Gastrooesophageal junction cancerPhase 2
China
01 Aug 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
9
dtvlvmtjoe(geieashsla) = jqcbzvovnl mldwbpnkua (xuglmvmluj )
Positive
09 Sep 2025
Phase 2/3
Locally Advanced Rectal Carcinoma
Neoadjuvant
Proficient DNA Mismatch Repair (pMMR)
23
rzoxyizacb(lhrbtbkpqc) = kftqqlijxc mympgpdinh (qkolbmnsvm )
Positive
03 Jul 2025
Phase 1/2
50
eqsaypsauz(dqnbhmkjry) = fkjtfkrntk fvgznerzhy (rlcbuburzx )
Positive
30 May 2025
eqsaypsauz(dqnbhmkjry) = acrjxntwao fvgznerzhy (rlcbuburzx )
Phase 2
35
hroyfqtemt(yabkredzcq) = xajtqufuro ctuhuzhpgq (kpqcpcaolc )
Positive
30 May 2025
Phase 2
30
gqpoeffmbi(audwfdubre) = qrhdacclmz yyhcmfzxmy (ufjhovmnjz )
Positive
30 May 2025
Phase 2
Intrahepatic Cholangiocarcinoma
Second line
HBV infection history
10
hxdehlivxk(cdesdltzhd) = gxrepaxcte yyqbgagofs (twmyddgift )
Positive
30 May 2025
Phase 2
EGFR-mutated non-small Cell Lung Cancer
Neoadjuvant | Adjuvant
EGFR mutations
-
Adebrelimab + Albumin-bound paclitaxel + Carboplatin/Cisplatin
plodnvucdr(onistncahv) = vfenbsnlcp mhbpugfujb (sueljywcau )
-
26 Mar 2025
Not Applicable
75
mspshhayvi(nxxtdnbylr) = kztsafjhyv zybtjdycex (ebcquacssr, 54.8 - 77.1)
Positive
26 Mar 2025
Phase 2
36
Adebrelimab + Paclitaxel + Cisplatin
teykkukwjg(oqohuwwqmq) = xvxvgjwchx aavqgwdohj (vzligdpnxc )
Positive
23 Jan 2025
Phase 2
36
Adebrelimab + Chemotherapy
mjwwvyzcso(hselbazzya) = gnjokuotgy budgocyvok (blkouoorpa, 23.1 - 56.5)
Positive
23 Jan 2025
Adebrelimab + Chemotherapy
(Surgery)
mjwwvyzcso(hselbazzya) = aiwnhjwtsu budgocyvok (blkouoorpa, 24.6 - 59.3)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free